ADB-FUBIATA: Difference between revisions

Latest revision as of 11:20, 15 February 2025

Overview[edit]

ADB-FUBIATA is a synthetic cannabinoid that belongs to the indazole-3-carboxamide family. It is a designer drug that has been used in recreational drugs and is often found in synthetic cannabis products. ADB-FUBIATA is known for its potent agonistic activity at the cannabinoid receptors, particularly CB1 and CB2.

Chemical Structure[edit]

ADB-FUBIATA is characterized by its indazole core, which is substituted at the 1-position with a carboxamide group. The chemical structure includes a tert-butyl group and a fluorobenzyl moiety, which contribute to its high affinity for cannabinoid receptors. The full chemical name is N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide.

Pharmacology[edit]

As a potent agonist of the cannabinoid receptors, ADB-FUBIATA mimics the effects of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. It binds to the CB1 and CB2 receptors, leading to a range of effects including euphoria, altered perception, and relaxation. However, due to its synthetic nature, the effects can be unpredictable and may include severe adverse reactions.

Legal Status[edit]

The legal status of ADB-FUBIATA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. It is often included in legislation targeting synthetic cannabinoids and "new psychoactive substances" (NPS).

Health Risks[edit]

The use of ADB-FUBIATA is associated with significant health risks. Users may experience tachycardia, hypertension, nausea, vomiting, and anxiety. In severe cases, it can lead to psychosis, seizures, and renal failure. The variability in synthetic cannabinoid products makes it difficult to predict the specific effects and risks associated with ADB-FUBIATA.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-{{Short description|Synthetic cannabinoid}}
+{{DISPLAYTITLE:ADB-FUBIATA}}
-{{Drugbox
-| verifiedfields = changed
-| verifiedrevid = 477002123
-| IUPAC_name = ''N''-[[1-(4-fluorobutyl)-1''H''-indazole-3-carbonyl]]-1-amino-3,3-dimethylbutan-2-yl
-| image = ADB-FUBIATA_structure.png
-| image_size = 200px
-}}
-'''ADB-FUBIATA''' is a synthetic cannabinoid that has been used in scientific research and is known for its potent agonistic activity at the [[cannabinoid receptor]]s. It is part of a class of compounds that are often referred to as [[designer drugs]] due to their synthetic nature and structural similarity to naturally occurring cannabinoids.
+== Overview ==
+'''ADB-FUBIATA''' is a synthetic cannabinoid that belongs to the indazole-3-carboxamide family. It is a designer drug that has been used in [[recreational drug]]s and is often found in [[synthetic cannabis]] products. ADB-FUBIATA is known for its potent agonistic activity at the [[cannabinoid receptor]]s, particularly [[CB1 receptor|CB1]] and [[CB2 receptor|CB2]].
-==Chemical Structure==
+[[File:ADB-FUBIATA_structure.png|thumb|right|Chemical structure of ADB-FUBIATA]]
-ADB-FUBIATA is chemically classified as an indazole-based synthetic cannabinoid. Its structure includes a 1-(4-fluorobutyl) group attached to an indazole core, with a carbonyl group linked to a tert-leucine moiety. This configuration is responsible for its high affinity and activity at the cannabinoid receptors.
-==Pharmacology==
+== Chemical Structure ==
-Synthetic cannabinoids like ADB-FUBIATA act primarily as agonists at the [[CB1 receptor|CB1]] and [[CB2 receptor|CB2]] receptors, which are part of the [[endocannabinoid system]]. These receptors are involved in a variety of physiological processes including pain sensation, mood regulation, and appetite control. ADB-FUBIATA's interaction with these receptors can lead to effects similar to those of [[tetrahydrocannabinol]] (THC), the active component of [[cannabis]].
+ADB-FUBIATA is characterized by its indazole core, which is substituted at the 1-position with a carboxamide group. The chemical structure includes a tert-butyl group and a fluorobenzyl moiety, which contribute to its high affinity for cannabinoid receptors. The full chemical name is N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide.
-==Legal Status==
+== Pharmacology ==
-The legal status of ADB-FUBIATA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. It is often included in legislation targeting synthetic cannabinoids and other [[novel psychoactive substances]].
+As a potent agonist of the cannabinoid receptors, ADB-FUBIATA mimics the effects of [[tetrahydrocannabinol]] (THC), the primary psychoactive component of [[cannabis]]. It binds to the CB1 and CB2 receptors, leading to a range of effects including euphoria, altered perception, and relaxation. However, due to its synthetic nature, the effects can be unpredictable and may include severe adverse reactions.
-==Health Effects==
+== Legal Status ==
-The use of synthetic cannabinoids like ADB-FUBIATA can lead to a range of adverse health effects. These may include [[tachycardia]], [[hypertension]], [[nausea]], [[vomiting]], and [[anxiety]]. In severe cases, it can cause [[psychosis]], [[seizures]], and [[renal failure]]. The variability in potency and purity of these substances increases the risk of overdose and other harmful effects.
+The legal status of ADB-FUBIATA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. It is often included in legislation targeting synthetic cannabinoids and "[[new psychoactive substances]]" (NPS).
-==Synthesis==
+== Health Risks ==
-The synthesis of ADB-FUBIATA involves the reaction of 1-(4-fluorobutyl)-1''H''-indazole-3-carboxylic acid with tert-leucine in the presence of a coupling agent. This process requires careful control of reaction conditions to ensure the desired product is obtained with high purity.
+The use of ADB-FUBIATA is associated with significant health risks. Users may experience [[tachycardia]], [[hypertension]], [[nausea]], [[vomiting]], and [[anxiety]]. In severe cases, it can lead to [[psychosis]], [[seizures]], and [[renal failure]]. The variability in synthetic cannabinoid products makes it difficult to predict the specific effects and risks associated with ADB-FUBIATA.
-==Related pages==
+== Related Pages ==
 * [[Synthetic cannabinoids]]
 * [[Cannabinoid receptor]]
-* [[Designer drug]]
+* [[Recreational drug]]
-* [[Endocannabinoid system]]
+* [[New psychoactive substances]]
 [[Category:Synthetic cannabinoids]]
 [[Category:Designer drugs]]